Global Information
회사소개 | 문의 | 비교리스트

드라베 증후군(DS) 시장 : 1차 조사 - 경쟁 정보, 시장 분석과 예측(-2032년)

Dravet Syndrome (DS) | Primary Research (KOL´s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032

리서치사 Mellalta Meets LLP
발행일 2022년 05월 상품코드 1089231
페이지 정보 영문 141 Pages 배송안내
가격
US $ 6,000 ₩ 7,902,000 PDF (Single User License)
US $ 9,000 ₩ 11,853,000 PDF (2 - 3 User License)
US $ 12,000 ₩ 15,805,000 PDF (Site License - Up to 10 Users)
US $ 18,000 ₩ 23,707,000 PDF (Enterprise License)


드라베 증후군(DS) 시장 : 1차 조사 - 경쟁 정보, 시장 분석과 예측(-2032년) Dravet Syndrome (DS) | Primary Research (KOL´s Insight) | Competitive Intelligence | Market Analytics & Forecast 2032
발행일 : 2022년 05월 페이지 정보 : 영문 141 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계의 드라베 증후군(DS: Dravet Syndrome) 시장에 대해 조사했으며, 시장 개요, 2032년까지 예측, 현재의 치료법과 미충족 요구, 국가별 동향, 시장 성장 촉진요인과 억제요인 등에 대한 정보를 제공합니다.

목차

개요

  • 주요 조사 결과

드라베 증후군(DS)의 배경

  • 드라베 증후군(DS)의 정의
  • 증상과 원인
  • SCN1A 유전자
  • 진단
  • 감별 진단

역학과 2032년까지 예측

  • 주요 조사 결과
  • 방법과 데이터 출처

드라베 증후군(DS) 역학과 모델 파라미터 주요 정보 출처

  • 브라질
  • 멕시코

현재 치료법과 의료 행위

  • 치료와 의료 행위
  • 드라베 증후군(DS)에서의 발작 치료
  • 2017년 이후 미국 FDA의 승인을 획득한 드라베 증후군 치료법
  • 드라베 증후군(DS) 치료에서의 칸나비디올

미충족 요구

치료의 장

새로운 치료법

드라베 증후군(DS) - 가격과 상환

향후의 치료 패러다임

  • 드라베 증후군(DS) 경쟁사의 상황과 예상되는 승인
  • 향후의 치료 알고리즘과 경쟁사의 포지셔닝
  • 새로운 치료를 위한 중요한 데이터 요약

현재 및 새로운 치료법의 연간 비용

시장 전망

2032년까지 국가별 시장 예측

국가별 시장 예측

  • 브라질
  • 멕시코

시장 성장 촉진요인과 억제요인

보고서의 조사 방법

부록

LSH 22.06.23

Growth of the incidence DS population will contribute to increasing sales in the DS therapy market over our forecast period. An estimated annual growth rate of ~1% in the diagnosed incident DS population across the major pharmaceutical markets will contribute to increasing DS therapy sales. In 2018, the drug-treated cases of Dravet Syndrome (DS) in Brazil & Mexico were 8,392 cases. These cases are expected to increase to 11,335 cases in 2032 owing to changes in population demographics and increasing cases of DS.

The continuous involvement of supportive treatments including antiepileptic therapies for the management of DS patients will contribute to the overall growth of the DS therapy market. We forecast that total sales of the total care market will reach $276 Million by 2032.

Dravet syndrome is a severe form of epilepsy characterized by frequent, prolonged seizures often triggered by high body temperature (hyperthermia), developmental delay, speech impairment, ataxia, hypotonia, sleep disturbances, and other health problems. DS is considered an epileptic encephalopathy due to seizures. In addition, it is considered a "channelopathy" because the effects of the mutation on the sodium channel appear to contribute to the disorder independently of the seizures.

Dravet Syndrome - DS Epidemiology

We estimate the total number of Dravet Syndrome (DS) prevalent cases in the Brazil and Mexico of 1:20,000 or 0.005%. There is a significant amount of shortage of large-scale epidemiological reports. The rarity of the disease further compounds the problem at hand as there exists a lack of firmly established and specific diagnostic criteria and some of the studies may have chances of biasness depending on the geographical area studied. There also exists methodological challenges for researchers due to measurements involving a small sample population.

According to the KOLs View, approximately 50% of the cases of Dravet Syndrome (DS) are diagnosed. Patients with Dravet syndrome may be misdiagnosed with myoclonic atonic epilepsy, Lennox-Gastaut syndrome, myoclonic epilepsy of infancy, genetic epilepsy with febrile seizures plus, atypical febrile seizures, and mitochondrial disorders. Additionally, some children may be diagnosed with focal epilepsy.

Dravet Syndrome -DS Market Forecast

The Dravet Syndrome (DS) therapy market is expected to experience high growth throughout our study period, increasing from $XX billion in 2018 to $XX billion in 2032, representing ~1% annual growth. Primary drivers of this growth will be uptake of the novel upcoming treatment like Soticlestat (Takeda/Ovid Therapeutics), Lorcaserin (Eisai/Arena Pharmaceuticals), STK 001 (Stoke Therapeutics, Inc), EPX 100 (Epygenix Therapeutics), ETX101 (Encoded Therapeutics).

Most interviewed experts believe that patients will benefit from the upcoming therapies based on targeting CH24H inhibitors, selective serotonin 5-HT2c receptor, NAV1.1 Voltage-gated Sodium Channel Modulators and Specific GABAA Receptor have the potential to increase the therapeutic options for Dravet Syndrome (DS) patients. Expected launch of late-stage product such as Soticlestat, Lorcaserin and STK 001 are likely to change the current treatment paradigm for Dravet Syndrome (DS) and these approved therapies will be more preferrable in the future.

Report Highlights

  • Dravet Syndrome-DS Current Market Trends
  • Dravet Syndrome-DS Current & Forecasted Cases across Brazil & Mexico
  • Dravet Syndrome-DS Market Opportunities And Sales Potential for Agents
  • Dravet Syndrome-DS Patient-based Market Forecast to 2032
  • Dravet Syndrome-DS Untapped Business Opportunities
  • Dravet Syndrome-DS Product Positioning Vis-a-vis Competitors' Products
  • Dravet Syndrome-DS KOLs Insight

Table of Contents

Executive Summary

  • Key Findings

Dravet Syndrome (DS) Disease Background

  • Dravet Syndrome (DS) Definition
  • Symptoms & Causes
  • SCN1A Gene
  • Diagnosis
  • Differential Diagnosis

Epidemiology Estimated and Forecast to 2032

  • Key Findings
  • Methods and data Sources
    • Country Specific Prevalent cases of Dravet Syndrome (DS) (Brazil and Mexico)
    • Country Specific Diagnosed and Drug Treated Cases of Dravet Syndrome (DS)

Key Sources for Dravet Syndrome (DS) Epidemiology and Model Parameters

  • Brazil
    • Brazil Prevalent cases of Dravet Syndrome (DS)
    • Brazil Diagnosed and Drug Treated Cases of Dravet Syndrome (DS)
  • Mexico
    • Mexico Prevalent cases of Dravet Syndrome (DS)
    • Mexico Diagnosed and Drug Treated Cases of Dravet Syndrome (DS)

Current Therapies and Medical Practice

  • Treatments & Medical Practices
  • Treatment of Seizures in Dravet Syndrome (DS)
  • Approved Therapies for Dravet Syndrome by U.S. FDA since 2017
  • Cannabidiol in the treatment of Dravet Syndrome (DS)

Unmet Needs

Therapies Chapters

  • Fenfluramine (Zogenix)
  • Epidiolex (Jazz Pharmaceuticals plc/GW Pharmaceuticals)
  • Stiripentol (Biocodex)

Emerging Therapies

  • Pipeline Overview
  • Therapeutic Developments Pipeline for Dravet Syndrome (DS)
    • Product Analysis
      • Soticlestat (Takeda/Ovid Therapeutics)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2032
      • Lorcaserin (Eisai/Arena Pharmaceuticals)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2032
      • STK 001 (Stoke Therapeutics)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2032
      • EPX 100 (Epygenix Therapeutics)
        • Product Profile
        • Clinical Development
        • Sales & Market Opportunity by 2032
      • EPX 200 (Epygenix Therapeutics)
        • Product Profile
        • Sales & Market Opportunity by 2032
      • EPX 300 (Epygenix Therapeutics)
        • Product Profile
        • Sales & Market Opportunity by 2032
      • ETX101 (Encoded Therapeutics)
        • Product Profile
        • Sales & Market Opportunity by 2032
      • Huperzine A (Supernus Pharmaceuticals/Biscayne Neurotherapeutics)
        • Product Profile
      • LP352 (Longboard Pharmaceuticals/Arena Pharmaceuticals)
        • Product Profile
      • NT-102 (Neuroene Therapeutics)
        • Product Profile
      • NCT10004 (Engrail Therapeutics/NeuroCycle Therapeutics)
        • Product Profile
      • BMB-101 (Bright Minds Biosciences)
        • Product Profile
      • OPK88001 (CAMP4 Therapeutics/OPKO Health)
        • Product Profile

Dravet Syndrome (DS)- Pricing & Reimbursement

Future Treatment Paradigm

  • Dravet Syndrome (DS) Competitor Landscape and Approvals Anticipated
  • Future Treatment Algorithms and Competitor Positioning
  • Key Data Summary for Emerging Treatment

Annual Cost of Current & Emerging Therapies

Market Outlook

  • Key Findings

Country Specific Market Forecast to 2032

  • Total Market for Dravet Syndrome (DS) 2018-2032 (USD Million)
  • Total Market for Dravet Syndrome (DS) by Therapies 2018-2032 (USD Million)

Market Forecast by Country

  • Brazil
    • Brazil Market for Dravet Syndrome (DS) 2018-2032 (USD Million)
    • Brazil Market for Dravet Syndrome (DS) by Therapies 2018-2032 (USD Million)
  • Mexico
    • Mexico Market for Dravet Syndrome (DS) 2018-2032 (USD Million)
    • Mexico Market for Dravet Syndrome (DS) by Therapies 2018-2032 (USD Million)

Market Drivers and Constraints

  • What Factors Are Driving the Market for Dravet Syndrome (DS)?
  • What Factors Are Constraining the Market for Dravet Syndrome (DS)?

Report Methodology

Appendix

Back to Top
전화 문의
F A Q